POLK (DNA Polymerase Kappa) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 25 Aug 2026
  • Comments

Unlocking Synthetic Lethality in DNA Damage Response: High-Precision Reagents for Translesion Synthesis Inhibition, Chemoresistance Reversal, and DDR Target Validation

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for POLK drug discovery, covering wild-type and mutant proteins, gene delivery, validation tools, and cross-screen panels.

Component / Network Product Description Product Link
Wildtype Enzyme (Antigen) POLK Recombinant Protein (full-length catalytic domain). High purity (>95%), Sequence Verified, Endotoxin <1 EU/µg, SDS-PAGE confirmed. Soluble intracellular target for enzymatic & SPR assays. View POLK Products
Mutant Panel POLK Mutant Recombinant Proteins (e.g., D198A catalytic dead) for resistance mechanism studies, negative controls, and active site binding confirmation. Endotoxin controlled. View POLK Products
Gene Delivery POLK Promise-ORF / Lentivirus (full-length ORF) for stable cell line construction in synthetic lethality or overexpression assays. View POLK Products
Benchmark Ab Anti-POLK Antibody (recombinant positive control) for biochemical and cellular target validation. View POLK Products
Validator POLK siRNA Set (validated knockdown sequences) for specificity controls in cellular assays. View POLK Products
Related: REV1 REV1 Protein / Lentivirus. Y-family TLS scaffold protein; POLK-interacting partner for selectivity profiling and PPI studies. View REV1 Products
Related: POLH POLH (DNA Polymerase Eta) Recombinant Protein. Y-family paralog; essential for counter-screening selectivity. View POLH Products
Related: BRCA2 BRCA2 Recombinant Protein (DNA-binding and RAD51-binding domains). Synthetic lethal partner for combination therapy validation. View BRCA2 Products

Critical Assay Challenges & The TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Y-family Selectivity (POLK vs. POLH, POLI, REV1) Ortholog panel proteins (human POLK, POLH, POLI) strictly verified by mass spec with distinct catalytic domain boundaries; full-length POLK with intact interaction domains.
Active Enzyme Production & Active Site Binding Sequence-verified high-purity (>95%) recombinant proteins preserving active site conformation; D198A catalytic dead mutant available as negative control.
Synthetic Lethality Validation Lentivirus for stable POLK knockdown/overexpression in BRCA-deficient backgrounds; combined with siRNA for specific target validation.
Protein-Protein Interaction (REV1/PCNA) Full-length POLK (1–870 aa) expressed in HEK293 for native folding and intact C-terminal interaction domains; suitable for SPR, AlphaScreen, and co-IP.
Cellular Target Engagement Sequence-verified siRNA included for specific knockdown; lentivirus for stable cell line construction.

Live POLK R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

Overcoming Chemoresistance

The race to target Translesion Synthesis (TLS) polymerases like POLK is intensifying as oncology research seeks to overcome acquired chemoresistance. Overexpression of POLK is strongly correlated with resistance to platinum-based chemotherapies and poor prognosis in multiple solid tumors. The next wave of R&D is focused on identifying highly selective small molecule inhibitors and PROTACs that can sensitize refractory tumors to standard-of-care DNA damaging agents.

Next-Generation Synthetic Lethality

Simultaneously, POLK is emerging as a key target in the DNA Damage Response (DDR) space, with major players shifting from broad cytotoxic agents to precision synthetic lethality strategies. As first-generation PARP inhibitors face resistance challenges (e.g., BRCA-reversion mutations), POLK represents a next-generation target for synthetic lethality combinations, particularly with ATR inhibitors and immune checkpoint blockade. The therapeutic focus spans platinum-resistant ovarian cancer, non-small cell lung cancer, and BRCA-deficient breast/pancreatic cancers.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule Inhibitors Academic spin-offs, DDR-focused biotechs Platinum-resistant ovarian, lung, prostate cancers; refractory solid tumors Enzymatic Assay / SPR (Need high-purity active wild-type POLK)
PROTAC / Degrader Emerging biotech platforms Platinum-resistant cancers; refractory solid tumors Ternary complex validation; PPI mapping (Need full-length POLK with REV1 binding sites)
Synthetic Lethality Combos Oncology consortiums, Big Pharma BRCA-deficient breast, pancreatic cancer; HR-deficient tumors Cell line construction & clonogenic assays (Need lentivirus and siRNA for stable POLK modulation)
RNAi / Antisense Preclinical pipelines Prostate / lung cancer Knockdown efficacy (Need validated siRNA / lentivirus)